Review
Neurosciences
Amir Valizadeh, Mohammad Reza Fattahi, Maryam Sadeghi, Mehrnush Saghab Torbati, Mohammad Ali Sahraian, Amir Reza Azimi
Summary: The study found that DMTs can reduce the number and volume of T1 hypointense lesions in MS patients, but these findings need to be interpreted cautiously due to high heterogeneity values. The results suggest that DMTs have a certain impact on the progression of the disease in MS patients.
CNS NEUROSCIENCE & THERAPEUTICS
(2022)
Review
Clinical Neurology
Marco Biolato, Assunta Bianco, Matteo Lucchini, Antonio Gasbarrini, Massimiliano Mirabella, Antonio Grieco
Summary: This review analyzed data on hepatotoxicity of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis, finding that while serious liver adverse events are rare, the exact incidence is unknown, and all current DMTs for multiple sclerosis have potential hepatic toxic effects.
Article
Medicine, Research & Experimental
Paulina Maria Reyes-Mata, Argelia Esperanza Rojas-Mayorquin, Lucrecia Carrera-Quintanar, Celia Gonzalez-Castillo, Mario Alberto Mireles-Ramirez, Jose de Jesus Guerrero-Garcia, Daniel Ortuno-Sahagun
Summary: This study aimed to investigate the serum levels of Pleiotrophin (PTN) in patients with Multiple Sclerosis (MS). The results showed that PTN serum levels were significantly higher in RRMS patients compared to the healthy control group, and were associated with sex, body mass index (BMI), and IFN-beta treatment.
ARCHIVES OF MEDICAL RESEARCH
(2022)
Article
Clinical Neurology
Tomas Kalincik, Ibrahima Diouf, Sifat Sharmin, Charles Malpas, Tim Spelman, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Vilija Jokubaitis, Anneke Van der Walt, Francois Grand'Maison, Patrizia Sola, Diana Ferraro, Vahid Shaygannejad, Raed Alroughani, Raymond Hupperts, Murat Terzi, Cavit Boz, Jeannette Lechner-Scott, Eugenio Pucci, Vincent Van Pesch, Franco Granella, Roberto Bergamaschi, Daniele Spitaleri, Mark Slee, Steve Vucic, Radek Ampapa, Pamela McCombe, Cristina Ramo-Tello, Julie Prevost, Javier Olascoaga, Edgardo Cristiano, Michael Barnett, Maria Laura Saladino, Jose Luis Sanchez-Menoyo, Suzanne Hodgkinson, Csilla Rozsa, Stella Hughes, Fraser Moore, Cameron Shaw, Ernest Butler, Olga Skibina, Orla Gray, Allan Kermode, Tunde Csepany, Bhim Singhal, Neil Shuey, Imre Piroska, Bruce Taylor, Magdolna Simo, Carmen-Adella Sirbu, Attila Sas, Helmut Butzkueven
Summary: The study demonstrates that continued treatment with MS immunotherapies significantly reduces disability accrual, risk of needing a walking aid, and frequency of relapses over a 15-year period.
Article
Biochemistry & Molecular Biology
Oliver Neuhaus, Wolfgang Koehler, Florian Then Bergh, Wolfgang Kristoferitsch, Juergen Faiss, Thorsten Rosenkranz, Dirk Reske, Robert Patejdl, Hans-Peter Hartung, Uwe K. Zettl
Summary: This study aimed to investigate the correlation between clinical, neuropsychological, and immunological parameters in RRMS patients with fatigue before and during treatment with GA. After 12 months of treatment, 13 patients showed improvement in all three fatigue assessment scales, while 5 patients deteriorated and 7 patients showed inconsistent effects. Fatigue and overall quality of life improved, but no clear correlation between clinical and molecular effects of GA was found in RRMS patients with fatigue.
Article
Clinical Neurology
Mathilde Lefort, Sandra Vukusic, Romain Casey, Gilles Edan, Emmanuelle Leray
Summary: Early treatment initiation has a significant impact on disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), reducing the risk of disability development, particularly in older patients.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Review
Clinical Neurology
Dejan Jakimovski, Samreen Awan, Svetlana P. Eckert, Osman Farooq, Bianca Weinstock-Guttman
Summary: POMS is a rare neuroinflammatory and neurodegenerative disease that affects a small percentage of patients before the age of 18. Differential diagnosis is necessary before treatment initiation to exclude other similar acquired demyelinating syndromes. Currently, only two MS DMTs have been approved for pediatric use.
Article
Clinical Neurology
Martin Valis, Zbysek Pavelek, Michal Novotny, Blanka Klimova, Jana Sarlakova, Simona Haluskova, Marek Peterka, Ivana Stetkarova, Pavel Stourac, Jan Mares, Pavel Hradilek, Radek Ampapa, Marta Vachova, Eva Recmanova, Eva Meluzinova
Summary: This study analyzed the characteristics and treatment of pediatric patients with multiple sclerosis. The results showed that these patients usually start disease-modifying drug treatment at the age of 15.89, with moderate and mild relapses being common. Moreover, the first-choice treatment is similar to that of adult patients, but low efficacy or lack of tolerance may lead to treatment discontinuation in children.
FRONTIERS IN NEUROLOGY
(2022)
Article
Ophthalmology
Joanna Roskal-Walek, Michal Biskup, Magdalena Dolecka-Slusarczyk, Anita Rosolowska, Andrzej Jaroszynski, Dominik Odrobina
Summary: Susac syndrome (SS) is difficult to diagnose as its clinical triad does not typically occur concurrently, often leading to misdiagnosis as other diseases like multiple sclerosis (MS). Combination therapy with corticosteroids, intravenous immunoglobulins, and azathioprine may improve SS symptoms.
Article
Clinical Neurology
E. J. Ramos Gonzalez, L. J. Ramirez Jirano, D. Z. Garcia Martinez, G. G. Ortiz, L. F. Jave Suarez, C. A. Leal Cortes, O. K. Bitzer Quintero
Summary: The present study compared the effects of MLT administration with IFN-beta and GA in an EAE rat model. Results showed that IFN-beta and GA had better clinical evaluation results compared to MLT. Further research is needed to evaluate the molecular mechanisms of MLT in EAE and quantify other cytokines in different biological media to determine if MLT can be considered as an anti-inflammatory agent for regulating MS.
Article
Immunology
Airi Rump, Kristel Ratas, Tuuli Katarina Lepasepp, Jaanus Suurvali, Olli-Pekka Smolander, Katrin Gross-Paju, Toomas Toomsoo, Jean Kanellopoulos, Sirje Ruutel Boudinot
Summary: Multiple sclerosis (MS) is an inflammatory autoimmune disorder that affects the central nervous system and leads to progressive neurological disability in young adults. It reduces the patient's lifespan by about 10 years and has a higher prevalence in women than men. Early diagnosis and treatment can improve outcomes.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
(2023)
Article
Clinical Neurology
Mackenzie Henderson, Daniel B. Horton, Vikram Bhise, Gian Pal, Greta Bushnell, Chintan V. Dave
Summary: This study evaluated patterns of disease-modifying therapy (DMT) initiations in multiple sclerosis (MS) patients in the US from 2001 to 2020. The results showed that oral DMTs were the most commonly initiated treatment by 2020. However, the reasons for this shift are still unclear.
Article
Clinical Neurology
Zbysek Pavelek, Michal Novotny, Ondrej Soucek, Jan Krejsek, Lukas Sobisek, Ilona Sejkorova, Jiri Masopust, Kamil Kuca, Martin Valis, Blanka Klimova, Pavel Stourac
Summary: The study investigated the changes of biomarkers in MS patients treated with GA and IFN, finding that both treatments have an impact on the B cell system, with IFN having a more pronounced effect.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Review
Immunology
Georges Jalkh, Rachelle Abi Nahed, Gabrielle Macaron, Mary Rensel
Summary: In the past decade, the therapeutic options for multiple sclerosis have greatly expanded, with newer and more effective disease modifying therapies being increasingly used early in the disease course. Despite their advantages in controlling disease activity and improving long-term outcomes, these newer therapies come with safety concerns and monitoring requirements that highlight the need for periodic re-evaluation and adjustment of monitoring strategies for optimizing treatment safety in an individualized manner.
Review
Immunology
Hans-Peter Hartung, Bruce A. C. Cree, Michael Barnett, Sven G. Meuth, Amit Bar-Or, Lawrence Steinman
Summary: Disease-modifying therapies for relapsing multiple sclerosis reduce relapse rates by suppressing peripheral immune cells but have limited efficacy in progressive forms of the disease. Cladribine and sphingosine 1-phosphate receptor modulators could have beneficial direct central nervous system properties.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Clinical Neurology
Tomas Uher, Manuela Vaneckova, Jan Krasensky, Lukas Sobisek, Michaela Tyblova, Jana Volna, Zdenek Seidl, Niels Bergsland, Michael G. Dwyer, Robert Zivadinov, Nicola De Stefano, Maria Pia Sormani, Eva Kubala Havrdova, Dana Horakova
MULTIPLE SCLEROSIS JOURNAL
(2019)
Article
Clinical Neurology
Tomas Uher, Manuela Vaneckova, Jan Krasensky, Lukas Sobisek, Michaela Tyblova, Jana Volna, Zdenek Seidl, Niels Bergsland, Michael G. Dwyer, Robert Zivadinov, Nicola De Stefano, Maria Pia Sormani, Eva Kubala Havrdova, Dana Horakova
MULTIPLE SCLEROSIS JOURNAL
(2019)
Article
Clinical Neurology
D. Jakimovski, S. Gandhi, I. Paunkoski, N. Bergsland, J. Hagemeier, D. P. Ramasamy, D. Hojnacki, C. Kolb, R. H. B. Benedict, B. Weinstock-Guttman, R. Zivadinov
EUROPEAN JOURNAL OF NEUROLOGY
(2019)
Article
Clinical Neurology
Suyog Pol, Michele Sveinsson, Michelle Sudyn, Natan Babek, Danielle Siebert, Nicola Bertolino, Claire M. Modica, Marilena Preda, Ferdinand Schweser, Robert Zivadinov
JOURNAL OF NEUROIMAGING
(2019)
Article
Clinical Neurology
Nicole Ziliotto, Robert Zivadinov, Dejan Jakimovski, Marcello Baroni, Veronica Tisato, Paola Secchiero, Niels Bergsland, Deepa P. Ramasamy, Bianca Weinstock-Guttnan, Francesco Bernardi, Murali Ramanathan, Giovanna Marchetti
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2019)
Editorial Material
Hematology
Nicole Ziliotto, Robert Zivadinov, Dejan Jakimovski, Niels Bergsland, Deepa P. Ramasamy, Bianca Weinstock-Guttman, Murali Ramanathan, Giovanna Marchetti, Francesco Bernardi
THROMBOSIS AND HAEMOSTASIS
(2019)
Article
Clinical Neurology
Robert Zivadinov, Jennie Medin, Nasreen Khan, Jonathan R. Korn, Tanuja Chitnis, Robert T. Naismith, Enrique Alvarez, Michael G. Dwyer, Niels Bergsland, Ellen Carl, Diego Silva, Bianca Weinstock-Guttman
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2019)
Article
Clinical Neurology
Tom A. Fuchs, Caila B. Vaughn, Ralph H. B. Benedict, Bianca Weinstock-Guttman, Sanjeevani Choudhery, Keith Carolus, Patrick Rooney, Kira Ashton, Deepa P. Ramasamy, Dejan Jakimovski, Robert Zivadinov, Michael G. Dwyer
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2019)
Article
Clinical Neurology
R. Zivadinov, D. Horakova, N. Bergsland, J. Hagemeier, D. P. Ramasamy, T. Uher, M. Vaneckova, E. Havrdova, M. G. Dwyer
AMERICAN JOURNAL OF NEURORADIOLOGY
(2019)
Article
Neurosciences
Yanis Taege, Jesper Hagemeier, Niels Bergsland, Michael G. Dwyer, Bianca Weinstock-Guttman, Robert Zivadinov, Ferdinand Schweser
Article
Neurosciences
Suyog Pol, Ferdinand Schweser, Nicola Bertolino, Marilena Preda, Michele Sveinsson, Michelle Sudyn, Natan Babek, Robert Zivadinov
EXPERIMENTAL NEUROLOGY
(2019)
Meeting Abstract
Clinical Neurology
H. N. Beadnall, L. Ly, C. Wang, J. Barton, T. A. Hardy, R. Zivadinov, M. H. Barnett
MULTIPLE SCLEROSIS JOURNAL
(2019)
Review
Cell Biology
Yi Guan, Dejan Jakimovski, Murali Ramanathan, Bianca Weinstock-Guttman, Robert Zivadinov
NEURAL REGENERATION RESEARCH
(2019)
Meeting Abstract
Clinical Neurology
Robert Zivadinov, Chakkarin Burudpakdee, Michael G. Dwyer, Niels Bergsland, Jeffrey Chavin, Karthinathan Thangavelu, Matt Mandel, Stanley Cohan
Meeting Abstract
Clinical Neurology
R. Zivadinov, R. H. B. Benedict, J. Hagemeier, N. Bergsland, F. Schweser, D. Jakimovski, M. G. Dwyer, D. P. Ramasamy, E. Carl, D. Hojnacki, C. Kolb, M. Ramanathan, B. Weinstock-Guttman
MULTIPLE SCLEROSIS JOURNAL
(2018)